Skip to main content
Top
Published in: Medical Oncology 10/2014

01-10-2014 | Original Paper

Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in colorectal cancer

Authors: Peng Chen, Qiulei Xi, Qiang Wang, Pei Wei

Published in: Medical Oncology | Issue 10/2014

Login to get access

Abstract

Dysregulation of microRNA-100 (miR-100) has been shown to be involved in cancer tumorigenesis and progression of several cancer types. However, its expression patterns in tumors are controversial. The aim of this study was to investigate the expression and clinical significance of miR-100 in colorectal cancer (CRC). Quantitative real-time PCR was used to analyze the expression of miR-100 in 138 pairs of human CRC and adjacent normal tissues. The prognostic values of miR-100 in CRC were also analyzed. The results showed that the miR-100 expression was significantly downregulated in CRC tissues when compared to adjacent normal tissues (P < 0.001). Also, low miR-100 expression was observed to be significantly correlated with larger tumor size (P = 0.023), higher incidence of lymph node metastasis (P = 0.009), and advanced TNM stage (P = 0.016). More importantly, Kaplan–Meier analysis showed that CRC patients with low miR-100 expression tended to have shorter overall survival. In multivariate analysis stratified for known prognostic variables, low miR-100 expression was identified as an independent prognostic factor for overall survival. In conclusion, our data indicated for the first time that the downregulation of miR-100 was associated with advanced clinical features and poor prognosis of CRC patients, suggesting that miR-100 downregulation may serve as an unfavorable prognostic biomarker in CRC.
Literature
2.
7.
go back to reference Zhou XJ, Dong ZG, Yang YM, Du LT, Zhang X, Wang CX. Limited diagnostic value of microRNAs for detecting colorectal cancer: a meta-analysis. Asian Pac J Cancer Prev. 2013;14(8):4699–704.PubMedCrossRef Zhou XJ, Dong ZG, Yang YM, Du LT, Zhang X, Wang CX. Limited diagnostic value of microRNAs for detecting colorectal cancer: a meta-analysis. Asian Pac J Cancer Prev. 2013;14(8):4699–704.PubMedCrossRef
9.
go back to reference Ma XL, Liu L, Liu XX, Li Y, Deng L, Xiao ZL, et al. Prognostic role of microRNA-21 in non-small cell lung cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(5):2329–34.PubMedCrossRef Ma XL, Liu L, Liu XX, Li Y, Deng L, Xiao ZL, et al. Prognostic role of microRNA-21 in non-small cell lung cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(5):2329–34.PubMedCrossRef
10.
go back to reference Shi W, Alajez NM, Bastianutto C, Hui AB, Mocanu JD, Ito E, et al. Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int J Cancer. 2010;126(9):2036–48. doi:10.1002/ijc.24880.PubMed Shi W, Alajez NM, Bastianutto C, Hui AB, Mocanu JD, Ito E, et al. Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int J Cancer. 2010;126(9):2036–48. doi:10.​1002/​ijc.​24880.PubMed
11.
go back to reference Oliveira JC, Brassesco MS, Morales AG, Pezuk JA, Fedatto PF, da Silva GN, et al. MicroRNA-100 acts as a tumor suppressor in human bladder carcinoma 5637 cells. Asian Pac J Cancer Prev. 2011;12(11):3001–4.PubMed Oliveira JC, Brassesco MS, Morales AG, Pezuk JA, Fedatto PF, da Silva GN, et al. MicroRNA-100 acts as a tumor suppressor in human bladder carcinoma 5637 cells. Asian Pac J Cancer Prev. 2011;12(11):3001–4.PubMed
16.
go back to reference Peng H, Luo J, Hao H, Hu J, Xie SK, Ren D, et al. MicroRNA-100 regulates SW620 colorectal cancer cell proliferation and invasion by targeting RAP1B. Oncol Rep. 2014;31(5):2055–62. doi:10.3892/or.2014.3075.PubMed Peng H, Luo J, Hao H, Hu J, Xie SK, Ren D, et al. MicroRNA-100 regulates SW620 colorectal cancer cell proliferation and invasion by targeting RAP1B. Oncol Rep. 2014;31(5):2055–62. doi:10.​3892/​or.​2014.​3075.PubMed
20.
go back to reference Perera RJ, Ray A. MicroRNAs in the search for understanding human diseases. BioDrugs. 2007;21(2):97–104.PubMedCrossRef Perera RJ, Ray A. MicroRNAs in the search for understanding human diseases. BioDrugs. 2007;21(2):97–104.PubMedCrossRef
21.
go back to reference Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27(15):2128–36. doi:10.1038/sj.onc.1210856.PubMedCrossRef Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27(15):2128–36. doi:10.​1038/​sj.​onc.​1210856.PubMedCrossRef
30.
go back to reference Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A, Camara-Lopes LH, et al. MicroRNA expression profiles in the progression of prostate cancer–from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol. 2013;31(6):796–801. doi:10.1016/j.urolonc.2011.07.002.PubMedCrossRef Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A, Camara-Lopes LH, et al. MicroRNA expression profiles in the progression of prostate cancer–from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol. 2013;31(6):796–801. doi:10.​1016/​j.​urolonc.​2011.​07.​002.PubMedCrossRef
Metadata
Title
Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in colorectal cancer
Authors
Peng Chen
Qiulei Xi
Qiang Wang
Pei Wei
Publication date
01-10-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 10/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0235-x

Other articles of this Issue 10/2014

Medical Oncology 10/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine